U.S. Oil and Gas Stock News

If you are wondering whether Arrowhead Pharmaceuticals at around US$77.95 is still offering value or has already run too far, this breakdown is designed to help you frame that question clearly. The stock has returned 6.1% over the past week, 27.4% over the last 30 days, 15.0% year to date, and 488.3% over the past year, which naturally raises questions about how much of the story is already priced in. Recent coverage has focused on Arrowhead Pharmaceuticals' progress in RNA interference...

Context for ManpowerGroup after recent performance swings ManpowerGroup (MAN) has seen mixed share performance recently, with a 7.6% gain over the past month and a 16.9% decline over the past 3 months. This has put fresh attention on the stock’s current valuation. See our latest analysis for ManpowerGroup. Looking beyond the recent 7.6% 30 day share price return, ManpowerGroup’s 1 year total shareholder return of 23.3% and 5 year total shareholder return of 70.4% highlight how sentiment has...

In late April 2026, CVR Energy, Inc. reported first quarter 2026 results showing sales of US$1,980 million, a larger net loss of US$192 million, higher refining throughput, a US$0.10 per share cash dividend, and new production guidance for the second quarter. This combination of stronger volumes but wider losses, alongside the decision to pay a dividend, gives investors fresh insight into the company’s balance between growth, profitability, and cash returns. We’ll now examine how higher...

If you are wondering whether Quest Diagnostics at around US$190.84 per share offers good value today, it helps to step back and look at the stock through a few different valuation lenses. The share price has seen mixed recent returns, with a 1.7% decline over 7 days and a 3.0% decline over 30 days, set against a 9.8% gain year to date and 10.4% over the past year, plus longer term returns of 54.8% over 3 years and 53.1% over 5 years. Recent coverage has focused on Quest Diagnostics as a US...

If you are wondering whether Capital Southwest stock still offers value at its current price, this article walks through the numbers so you can judge how the valuation stacks up for yourself. With the share price at US$23.99, recent returns of 6.3% over 30 days, 7.6% year to date and 35.5% over the past year put a clear spotlight on how investors are currently pricing the stock and what that might mean for future risk and reward. Those returns sit alongside a longer record, including 89.7%...

SkyWater Technology, Inc. has released its first‑quarter 2026 results, reporting sales of US$160.69 million versus US$61.3 million a year earlier, alongside a net loss of US$12.31 million and basic and diluted loss per share from continuing operations of US$0.25, both larger than the prior year. The combination of rapidly higher revenue and a wider loss profile highlights how SkyWater’s growth investments are still weighing on profitability, a pattern that investors may re‑evaluate against...

Axcelis Technologies reported first-quarter 2026 revenue of US$198.96 million, slightly above the prior year, while net income and earnings per share declined meaningfully year over year. Alongside guiding to higher second-quarter revenue and earnings, Axcelis highlighted momentum in memory and silicon carbide markets and showcased its MUSIC™ implant technology at an industry conference, underlining its focus on equipment innovation. Next, we’ll examine how this combination of...

If you are trying to work out whether LyondellBasell Industries' current share price reflects its underlying value, the recent moves in the stock give you plenty to think about. The stock closed at US$71.51, with a 4.1% decline over the past week and a 10.9% decline over the past month, yet it has returned 61.1% year to date and 36.5% over the last year. Recent coverage around LyondellBasell has focused on its position within the broader chemicals sector and how investors are weighing...

In the first quarter of 2026, Allegion reported sales of US$1,033.6 million, up from US$941.9 million a year earlier, while net income declined to US$138.1 million and diluted EPS from continuing operations eased to US$1.59. The company attributed the profit pressure to margin impacts from ERP-related production issues in its international business, even as it raised full-year 2026 revenue growth guidance to 6%–8% and projected full-year EPS of US$7.95–US$8.15. Next, we will examine how...

Navan (NasdaqGS:NAVN) has secured Criteo and Schindler as new enterprise clients for its AI-powered corporate travel platform. The agreements cover multi country travel programs and use Navan’s unified system for booking, policy compliance, and traveler support. Both clients are using Navan’s tools for operational efficiency, sustainability tracking, and user satisfaction across their global workforces. For investors watching corporate travel and expense software, Navan sits at the...

Legence (NasdaqGS:LGN) reported strong quarterly results, supported by organic growth across the business. The Installation & Maintenance segment delivered major outperformance within the period. Recent acquisitions were integrated into the business, contributing to current operations. Management raised 2026 guidance, signaling higher internal expectations for future performance. Legence, listed as NasdaqGS:LGN, focuses on installation and maintenance services, an area that can be closely...

Wondering if Quanta Services at around US$750 per share still offers value, or if most of the opportunity is already priced in. The stock has returned 3.2% over the last week, 35.1% over the last month, 70.7% year to date and 130.3% over the past year, with a very large 5 year return close to 7x. These moves are drawing fresh attention to Quanta Services as investors reassess what they are willing to pay for infrastructure and capital projects exposure. Recent coverage has focused on how the...

Wondering whether FTAI Aviation stock still offers value at its current price, or if most of the opportunity is already reflected in the share price. The stock last closed at US$272.54, with returns of 9.2% over 7 days, 13.1% over 30 days, 29.6% year to date, 149.9% over 1 year, and a very large 3 year and 5 year return. Recent coverage has focused on how this rapid share price performance has put more attention on what investors are paying for each dollar of future cash flow and asset...

Wondering if Revolution Medicines at around US$142.51 is still offering value after its strong run, or if you are late to the story? This article focuses squarely on what the current price could mean for you as a shareholder. The stock has seen a 1.1% decline over the last 7 days, but that comes after strong gains of 48.0% over 30 days, 80.3% year to date, 240.0% over 1 year and a very large 3 year return of 456.2% and 5 year return of 363.6%. Recent headlines around Revolution Medicines...

Wondering if CubeSmart at US$40.25 is offering good value right now, or if the easy gains are already behind it. The stock has been relatively steady over the last year with a 0.1% return, but the 8.1% return over 30 days and 13.7% return year to date show that sentiment around the shares has shifted recently. Recent trading moves have picked up as investors reassess listed real estate and storage focused stocks more broadly, with CubeSmart part of that conversation. This has put more...

A10 Networks, Inc. has already reported first-quarter 2026 results, with revenue of US$75.0 million and net income of US$12.03 million, while its board approved a US$0.06 quarterly dividend and the company continued share repurchases under its existing buyback program. The company also reiterated its full-year 2026 outlook for revenue and earnings growth, underscoring management confidence in ongoing demand for its networking and security solutions. We’ll now examine how A10’s reaffirmed...

If you are wondering whether Swarmer's current share price reflects its real value, the recent moves in the stock give you plenty to think about. After recent trading, Swarmer closed at US$27.90, with returns of a 27.2% decline over 7 days, a 39.4% decline over 30 days and a 10.0% decline year to date. This suggests a sharp reset in market expectations. Recent headlines around Swarmer have focused on its position within the broader capital goods sector and how investors are reassessing...

CVB Financial (NasdaqGS:CVBF) has completed its acquisition of Heritage Commerce Corp, creating a larger combined bank. The company has released pro forma financials for 2025 for the merged entity, giving investors a first look at the combined profile. This transaction marks a meaningful change in CVB Financial’s scale and business mix compared with its prior standalone position. CVB Financial, trading at $20.51, now reflects a business that is materially different from the one behind its...

Investors may be wondering whether RingCentral's current share price reflects its true worth, or if the recent price action has left it mispriced in either direction. The stock last closed at US$45.39, with returns of 12.9% over 7 days, 19.5% over 30 days, 64.5% year to date, 70.5% over 1 year, 58.2% over 3 years, and an 80.9% decline over 5 years. This presents a mixed picture of strong rebounds alongside longer term losses. Recent coverage has focused on RingCentral's position as a...

If you are wondering whether PTC at around US$147.65 is priced attractively, this article walks through what the current valuation signals might mean for you. The stock has seen an 8.3% move over the last 7 days and 2.6% over the past month, but is still showing a 13.2% decline year to date and a 10.4% decline over the last year, which may catch the eye of investors weighing potential opportunity against recent sentiment. Recent coverage of PTC has focused on its role as a US software...

Wondering if Scholar Rock Holding at around US$46.45 is giving you fair value or a potential opportunity? This article walks through the key numbers in plain language so you can judge for yourself. The stock has seen mixed recent returns, with a 0.3% decline over the last 7 days and a 6.9% decline over the last month, alongside gains of 8.5% year to date, 49.9% over 1 year and a very large 3 year return, plus a 63.3% gain over 5 years. These moves have come as investors weigh ongoing...

Niagen Bioscience (NAGE) is back on investors’ radar after reporting Q1 2026 results that exceeded consensus estimates, alongside the launch of its Niagen Plus telehealth platform and at-home prescription injection kits. See our latest analysis for Niagen Bioscience. Despite the upbeat Q1 report and new Niagen Plus initiatives, the stock’s recent momentum has been weak, with a 30 day share price return of a 6.26% decline and a year to date share price return of a 32.96% decline. The 3 year...

Investors may be wondering whether Evercore, at around US$331 per share, still offers value or whether most of the easy gains are already behind it. The stock has delivered a 3.1% move over the last week and 7.9% over the past month, while year to date it is at a 5.7% decline against a 54.6% return over the last year, a 225.1% return over three years, and 154.1% over five years. Recent coverage has focused on Evercore's role in major advisory mandates and its position within capital markets...

Wondering if Hercules Capital's share price really reflects what you are getting for your money? This breakdown walks through what the current market price might be missing or already pricing in. Recently, the stock closed at US$16.40, with returns of 2.2% over 7 days, 8.5% over 30 days, 4.0% over 1 year and 67.6% over both 3 and 5 years, while the year to date return sits at a 13.0% decline. These moves sit against a backdrop of ongoing interest in income focused business development...